logo.jpg
Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities
December 14, 2020 12:22 ET | Addex Therapeutics
Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
logo.jpg
Addex Reports Q3 2020 Financial Results and Provides Corporate Update
November 03, 2020 01:00 ET | Addex Therapeutics
Geneva, Switzerland, November 3, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
ADDEX THERAPEUTICS TO RELEASE Q3 2020 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 3rd, 2020
November 02, 2020 01:06 ET | Addex Therapeutics
Geneva, Switzerland, November 2, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its Q3 2020...
logo.jpg
Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration
November 02, 2020 01:00 ET | Addex Therapeutics
Geneva, Switzerland, November 2, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that the...
logo.jpg
Addex to Present at the Investora Conference
September 23, 2020 01:00 ET | Addex Therapeutics
Geneva, Switzerland, September 23, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that...
logo.jpg
Addex Therapeutics to Participate at the H.C. Wainwright 22nd Annual Global Investment Conference
September 14, 2020 01:00 ET | Addex Therapeutics
Geneva, Switzerland, September 14, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that...
logo.jpg
Addex Therapeutics to Participate at the Biotechgate Digital Partnering Conference
August 31, 2020 01:00 ET | Addex Therapeutics
Geneva, Switzerland, August 31, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that that...
logo.jpg
Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Computational Modelling
August 27, 2020 01:00 ET | Addex Therapeutics
 ADX10061 Previously Demonstrated Favorable Safety and Tolerability in Clinical Studies Geneva, Switzerland, August 27, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
logo.jpg
Addex Reports 2020 Half Year Financial Results and Provides Corporate Update
August 12, 2020 01:00 ET | Addex Therapeutics
Geneva, Switzerland, August 12, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
logo.jpg
Addex Therapeutics to Release Half-Year 2020 Financial Results and Host Conference Call on August 12, 2020
August 10, 2020 01:00 ET | Addex Therapeutics
Geneva, Switzerland, August 10, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its...